The National Institute for Health and Care Research (NIHR) has launched a landmark £3.4 million trial, named the DIAgnosis of Liver disease in primary care (DIALS) trial, aimed at significantly improving early detection of liver disease across the UK. This study is being hailed as the largest liver study in the history of the NHS and is designed to prevent thousands of people at risk from needing hospital care. The trial will screen approximately 42,000 individuals identified as being at higher risk of liver disease through their General Practitioners (GPs). These high-risk factors include excessive alcohol intake, Type 2 diabetes, and obesity. Participants will undergo a combination of three non-invasive liver scans to determine the most efficient method for early diagnosis. If these tests indicate potential cirrhosis, patients will be referred to specialists for further assessment and treatment. Currently, a significant challenge in liver disease management is late diagnosis; around 70% of patients admitted to hospital with late-stage liver disease were not previously diagnosed, and about a quarter of these patients die within two months, offering little opportunity for intervention. Liver disease is a major cause of premature mortality in the UK, with death rates quadrupling over the past 50 years, despite 90% of cases being preventable. The DIALS trial, led by Professor Emmanouil Tsochatzis and Dr Ian Rowe, seeks to address this by diagnosing preventable liver disease earlier, which could profoundly impact healthcare, the NHS, and society by reducing hospitalisations and associated costs, and by decreasing premature deaths. The ultimate goal is for this screening approach to become national policy.